Cagrilintide Peptide: Latest Research Data, Market Outlook & Selection Guide for Obesity Therapy

Core Molecular Specs & Technical Index

Cagrilintide peptide is a long-acting amylin analog designed for metabolic research and formulation development. This synthetic peptide targets the amylin receptor pathway, offering a novel mechanism for weight management studies. B2B buyers, including cosmetic ingredient formulators, laboratory researchers, and bulk raw material distributors, value cagrilintide for its high purity, stability, and compatibility with combination therapies. The core value lies in its potential to enhance efficacy when paired with GLP-1 analogs like semaglutide, making it a strategic component in next-generation anti-obesity product pipelines.

• Purity: ≥98% by HPLC, ensuring minimal impurities for reproducible research outcomes.
• Molecular Weight: 4,113.7 Da, with a precise sequence for targeted receptor binding.
• Solubility: Soluble in water and PBS at 10 mg/mL, facilitating easy formulation in lab buffers.
• Storage: Lyophilized powder stable at -20°C for 24 months; reconstituted solution stable at 4°C for 7 days.
• Appearance: White to off-white lyophilized powder, free from visible particulates.

Industry data: The global anti-obesity peptide market is projected to exceed $50 billion by 2030, driven by rising demand for non-surgical interventions. Cagrilintide peptide represents a key growth segment, with clinical trials showing up to 15–20% body weight reduction when combined with semaglutide.

Manufacturing & Quality Control

Our cagrilintide peptide is manufactured using solid-phase peptide synthesis (SPPS) with Fmoc chemistry, ensuring high fidelity in amino acid sequence assembly. The production process includes automated coupling, cleavage, and precipitation steps, followed by reverse-phase high-performance liquid chromatography (RP-HPLC) purification to achieve ≥98% purity. Each batch undergoes rigorous quality control, including mass spectrometry (MS) for molecular weight confirmation and amino acid analysis for sequence verification.

Third-party testing is conducted by independent ISO 17025 accredited laboratories, providing certificates of analysis (CoA) for every lot. Tests include endotoxin levels (<1 EU/mg), residual solvents (meeting ICH Q3C guidelines), and microbial limits (no growth in 1 g sample). This ensures compliance with cosmetic and research-grade standards, suitable for formulation development and preclinical studies.

• Certification: ISO 9001:2015 for manufacturing quality management.
• Testing: HPLC, MS, amino acid analysis, endotoxin, and sterility reports included.
• Traceability: Batch-specific documentation for full supply chain transparency.

Commercial Application Scenarios

Cagrilintide peptide serves diverse B2B applications across cosmetic formulation, laboratory research, and bulk wholesale distribution. In cosmetic formulation, it is incorporated into topical serums and injectable aesthetic products targeting body contouring and metabolic enhancement. Researchers use it in in vitro and in vivo studies to investigate amylin receptor signaling and combination therapy synergies. Bulk wholesale buyers supply pharmaceutical and nutraceutical manufacturers for preclinical trials and product development pipelines.

• Cosmetic Formulation: Added to anti-aging and slimming creams at 0.1–1% concentration for metabolic modulation.
• Lab Research: Used in cell-based assays and animal models for obesity and diabetes studies.
• Bulk Wholesale: Supplied in multi-gram quantities for large-scale formulation and clinical-grade production.

cagrilintide peptide VS Ordinary Low-Grade Peptides

Bulk Purchase Selection Guide

When sourcing cagrilintide peptide in bulk, buyers must avoid common pitfalls such as low purity, inconsistent batch quality, and lack of documentation. Selection standards include verifying purity via HPLC reports, checking endotoxin levels for injectable applications, and ensuring proper storage conditions. A buyer checklist should cover supplier certifications, sample testing before bulk orders, and clear return policies for non-conforming products.

• Common Pitfalls: Accepting peptides without CoA, ignoring solubility data, and overlooking storage requirements.
• Selection Standards: Purity ≥98%, endotoxin <1 EU/mg, and batch-to-batch consistency.
• Buyer Checklist: Request CoA, test sample in your buffer, confirm shipping conditions, and verify supplier ISO certification.

Core Product Advantages

Our cagrilintide peptide offers superior purity, stability, and cost performance compared to market alternatives. With ≥98% purity, it ensures minimal impurities for reliable research outcomes. The lyophilized powder remains stable for 24 months, reducing waste and storage costs. Competitive pricing for bulk orders, combined with free technical support for formulation and assay development, makes it a cost-effective choice for B2B buyers.

• Purity: ≥98% HPLC-verified for consistent results.
• Stability: 24-month shelf life at -20°C.
• Cost Performance: Bulk discounts up to 30% for orders over 10 grams.
• Technical Support: Free consultation on solubility, formulation, and combination therapy protocols.

Frequently Asked Questions

Q: What is the recommended purity for cagrilintide peptide in research applications?
A: For reliable and reproducible results, we recommend ≥98% purity by HPLC. Lower purity may introduce impurities that affect receptor binding and data interpretation.

Q: How should cagrilintide peptide be stored to maintain stability?
A: Store lyophilized powder at -20°C in a desiccated environment. Avoid repeated freeze-thaw cycles. Reconstituted solutions should be used within 7 days when stored at 4°C.

Q: Can cagrilintide peptide be combined with semaglutide in formulation?
A: Yes, cagrilintide is often studied in combination with semaglutide for synergistic weight loss effects. Ensure both peptides are dissolved in compatible buffers and tested for stability before use.